These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31420586)

  • 21. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
    Llanes C; Pourcel C; Richardot C; Plésiat P; Fichant G; Cavallo JD; Mérens A;
    J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 25. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
    Moriyama B; Henning SA; Childs R; Holland SM; Anderson VL; Morris JC; Wilson WH; Drusano GL; Walsh TJ
    Ann Pharmacother; 2010 May; 44(5):929-35. PubMed ID: 20371747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Rapid Phenotypic Whole-Cell Screening Approach for the Identification of Small-Molecule Inhibitors That Counter β-Lactamase Resistance in Pseudomonas aeruginosa.
    Collia D; Bannister TD; Tan H; Jin S; Langaee T; Shumate J; Scampavia L; Spicer TP
    SLAS Discov; 2018 Jan; 23(1):55-64. PubMed ID: 28850797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Ultrashort Peptide OW: A New Antibiotic Adjuvant.
    Al Tall Y; Abualhaijaa A; Qaoud MT; Alsaggar M; Masadeh M; Alzoubi KH
    Curr Pharm Biotechnol; 2019; 20(9):745-754. PubMed ID: 31258076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
    Chen YH; Peng CF; Lu PL; Tsai JJ; Chen TP
    Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simple method to determine beta-lactam resistance phenotypes in Pseudomonas aeruginosa using the disc agar diffusion test.
    Vedel G
    J Antimicrob Chemother; 2005 Oct; 56(4):657-64. PubMed ID: 16144872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Dias VC; Resende JA; Bastos AN; De Andrade Bastos LQ; De Andrade Bastos VQ; Bastos RV; Diniz CG; Da Silva VL
    Microb Drug Resist; 2017 Oct; 23(7):852-863. PubMed ID: 28437232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [MULTIRESISTANT BACTERIA].
    Bedenić B; Sardelić S; Ladavac M
    Acta Med Croatica; 2015 Sep; 69(3):211-6. PubMed ID: 29077379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of beta-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey.
    Bonfiglio G; Laksai Y; Franchino L; Amicosante G; Nicoletti G
    J Antimicrob Chemother; 1998 Dec; 42(6):697-702. PubMed ID: 10052891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
    Lerner SA; Quinn JP
    Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly Synergistic Effects of Melittin with Conventional Antibiotics Against Multidrug-Resistant Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa.
    Akbari R; Hakemi-Vala M; Pashaie F; Bevalian P; Hashemi A; Pooshang Bagheri K
    Microb Drug Resist; 2019 Mar; 25(2):193-202. PubMed ID: 30281385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antimicrobial activity of fosfomycin under various conditions against standard strains, beta-lactam resistant strains, and multidrug efflux system mutants].
    Mikuniya T; Hiraishi T; Maebashi K; Ida T; Takata T; Hikida M; Yamada S; Gotoh N; Nishino T
    Jpn J Antibiot; 2005 Apr; 58(2):105-22. PubMed ID: 15997654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The emergence of beta-lactam resistance among strains of Enterobacter cloacae and Pseudomonas aeruginosa.
    Aronoff SC
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S100-3; discussion S128-32. PubMed ID: 2510122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of various antibiotic combinations using the E-Test method in multiresistant Pseudomonas aeruginosa strains.
    Kocazeybek B; Arabaci U; Erentürk S; Akdur H
    Chemotherapy; 2002 Mar; 48(1):31-5. PubMed ID: 11901254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms.
    Gad GF; El-Domany RA; Zaki S; Ashour HM
    J Antimicrob Chemother; 2007 Nov; 60(5):1010-7. PubMed ID: 17906321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria.
    Lamers RP; Cavallari JF; Burrows LL
    PLoS One; 2013; 8(3):e60666. PubMed ID: 23544160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.